Brainsway (BWAY) Stock Forecast & Price Target

BrainsWay is supported by a strengthening clinical and commercial case for its Deep TMS platform, as the company is showing efficacy not only in its cleared psychiatric indications but also in broader neuropsychiatric settings, including 83.3% response and 50% remission in 12 patients with MDD and early-stage Alzheimer’s disease and a 70% relative reduction in suicidal ideation in 89 MDD patients over six weeks. The positive outlook is further reinforced by pipeline expansion, including a new FDA clearance application for comorbid PTSD/MDD backed by real-world data from 462 patients across 11 clinical sites with an 83.5% PTSD symptom response rate and a mean 52% reduction in PCL-5 scores, while ongoing AUD enrollment and planned neurology feasibility studies in dementia and Parkinson’s disease expand the addressable opportunity. From a financial standpoint, the company is a commercial-stage medical technology business with expected forward 12-month revenue of $78.5M and ~$62.1M in cash as of mid-2026, and the breadth of clinical evidence, product leasing and sales model, and multiple avenues for additional regulatory clearances all support a constructive fundamental outlook.

BrainsWay is fundamentally challenged by the fact that much of the bullish case depends on future clinical and commercial adoption rather than a clearly proven, durable earnings engine, even though the company is still seeking broader utilization across more than 200 identified clinic targets and additional indications. The new suicidality data are encouraging but remain limited to 89 patients, show only a secondary analysis of a previously published trial, and do not yet translate into a formal label for prevention of suicidal ideation, leaving a meaningful gap between publication and monetizable reimbursement-driven demand. Even with the report that 22.5% of patients had SSI>0 at baseline versus 6.7% after six weeks and that SWIFT was cleared in September 2025, the investment thesis still hinges on expanding payor coverage, international expansion, and adjacent indications that may take time to convert scientific validation into consistently higher revenue and profit.